Sarah Cannon to Present Latest Cancer Research Insights at ASCO®20 Virtual Meeting

More Than 110 Abstracts and Presentations will be Presented by Sarah Cannon Researchers;
Dr. Howard A. “Skip” Burris III Serves as ASCO® President at the Annual Meeting

NASHVILLE, TENN., May 28, 2020 – Today, Sarah Cannon announced that it will present its latest cancer research insights at the American Society of Clinical Oncology’s (ASCO®) Annual Meeting being held virtually May 29 – 31, 2020. This year, Sarah Cannon’s drug development and research expertise is featured through more than 110 abstracts and presentations, including data from more than 50 phase 1 studies.

The ASCO®20 Virtual Meeting will bring together the largest community of oncology leaders worldwide to discuss pivotal clinical research that is influencing the latest care and treatment standards for patients facing cancer. This year’s event is being led by Sarah Cannon’s President of Clinical Operations and Chief Medical Officer, Howard A. “Skip” Burris III, MD, FACP, FACSO, who is serving as the 2020 ASCO® President.

“When I chose my presidential theme to Unite and Conquer: Accelerating Progress Together, I never imagined what new meaning it would take over the course of this year, especially in the time of a global pandemic,” says Dr. Burris. “In spite of recent challenges, we know that by bringing together oncologists, pharmacists, nurses, staff, lab techs, scientists, practice administrators and academic researchers, we are more united than ever with our patients to accelerate progress in the fight against cancer.”

Dr. Burris will deliver this year’s presidential speech on Saturday, May 30 at 8:30 AM CT.

Melissa Johnson, MD, Sarah Cannon’s Associate Director of Lung Cancer Research and Drug Development, serves as this year’s ASCO® Scientific Committee Chair, leading the scientific program at the meeting. In this role, Dr. Johnson will lead two key programs: the clinical science symposium on “Cancer Care in the Time of COVID: Assessing Impact and Future Direction” on Saturday, May 30 from 3:30-4:30 PM CT, and will also chair the Plenary Session on Sunday, May 31 from 12-2:30 PM CT.

A number of Sarah Cannon research leaders will also participate in the following educational and oral presentations:

- **Johanna Bendell, MD**, Chief Development Officer and Director of the GI Cancer Research Program, will present “Phase I Monotherapy Dose Escalation of RGX-202, a First-In-Class Oral Inhibitor of the SLC6a8/CKB Pathway, in Patients with Advanced Gastrointestinal Solid Tumors” in an oral presentation. (Abstract 3504)

- **Jesus Berdeja, MD**, Director of Myeloma Research and Senior Investigator of Hematologic Malignancies, is the discussant on the plenary session focused on “Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone for Initial Therapy of Newly Diagnosed Multiple Myeloma” on Sunday, May 31 from 12-2:30 PM CT. Dr. Berdeja will also highlight data in an oral presentation on “Update of CARTITUDE-1: A Phase Ib/II Study of
JNJ-4528, a B-Cell Maturation Antigen-Directed CAR-T-Cell Therapy, in Relapsed/Refractory Multiple Myeloma.” (Abstract 8505)

- **Ian Flinn, MD**, Director of Lymphoma Research, is the discussant during the poster presentation on “Reassessing PI3K Inhibitors in Indolent Lymphomas.”
- **Stephanie Graff, MD**, Director of the Breast Cancer Program and Clinical Research for Sarah Cannon Cancer Institute at HCA Midwest Health, is the discussant on the poster presentation of “Mind the Gap: Identifying Disparities and Actionable Insights.”
- **Anthony Greco, MD**, Co-founder of Sarah Cannon, is the discussant during the clinical science symposium on “Redefining Cancer of Unknown Primary: Is Genomics the Answer?” on Saturday, May 30, from 2:30-3:30 PM CT.
- **Erika Hamilton, MD**, Director of the Breast Cancer and Gynecologic Cancer Research Program, will review key advancements in breast cancer research during the “Highlights of the Day” session on Saturday, May 30 9:30-10 AM CT.
- Dr. Johnson will present “CX-2029, a PROBODY Drug Conjugate Targeting CD71 (Transferrin Receptor): Results from a First-In-Human Study in Patients with Advanced Cancer” and “Primary Analysis of a Randomized, Double-Blind, Phase II Study of the Anti-TIGIT Antibody Tiragolumab Plus Atezolizumab Versus Placebo Plus Atezo as First-Line Treatment in Patients with PD-L1-Selected NSCLC (CITYSCAPE)” in two oral presentations. (Abstract 3502, Abstract 9503)
- **Aravind Ramakrishnan, MD**, Medical Director of the Bone Marrow Transplant and Cellular Therapy Program for Sarah Cannon Blood Cancer Center at St. David’s South Austin Medical Center, will present “Phase I Alexander Study of AUTO3, the First CD19/22 Dual Targeting CAR T-Cell Therapy, with Pembrolizumab in Patients with Relapsed/Refractory DLBCL” in an oral presentation. (Abstract 8001)
- **David Spigel, MD**, Chief Scientific Officer and Director of the Lung Cancer Research Program, will be the discussant in a plenary session focused on “Osimertinib as Adjuvant Therapy in Patients with Stage IB–IIIA EGFR Mutation Positive NSCLC After Complete Tumor Resection: ADAURA” on Sunday, May 31, from 12-2:30 PM CT.

At the ASCO®20 Virtual Meeting, posters with Sarah Cannon experts as first authors will be presented by:

- Dr. Bendell will present on “First-In-Human Phase I Study of HPN424, a Tri-Specific Half-Life Extended PSMA-Targeting T-Cell Engager in Patients with Metastatic Castration-Resistant Prostate Cancer.” (Abstract 5552)
- Dr. Hamilton will present on “Clinical Activity of MCLA-128, Trastuzumab, and Vinorelbine in HER2 Amplified Metastatic Breast Cancer Patients who Had Progressed on Anti-HER2 ADCs.” (Abstract 3093)
- Dr. Johnson will present “Safety of BI 754111, an Anti-LAG-3 Monoclonal Antibody, in Combination with BI 754091, an Anti-PD-1 Mab, in Patients with Advanced Solid Tumors.” (Abstract 3063)
- Dr. Spigel will present in two posters on “Randomized Phase II Study of Pembrolizumab Alone Versus Pegilodecakin in Combination with Pembrolizumab as First-Line Therapy in Patients with Stage IV Non-Small Cell Lung Cancer with High PD-L1 Expression (CYPRESS 1)” and “RESILIENT Part I, an Open-Label, Safety Run-In of Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Have Progressed with Platinum-Based First-Line Therapy: Subgroup Analyses By Platinum Sensitivity.” (Abstract 9563, Abstract 9069)
• **Denise Yardley, MD**, Senior Investigator of the Breast Cancer Research Program, will present on “Overall Survival in Patients with Advanced Breast Cancer with Visceral Metastases, Including Those with Liver Mets, Treated with Ribociclib Plus Endocrine Therapy in the MONALEESA -3 and -7 Trials.” (Abstract 1054)

• **Manish Patel, MD**, Director of Drug Development for Sarah Cannon Research Institute at Florida Cancer Specialists, will present on “A Phase I Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36y, for Intratumoral Injection Alone and in Combination With Durvalumab.” (Abstract 3092)

• **Carlos Bachier, MD**, Director of Cellular Therapy Research, will present on “Outpatient Treatment with Lisocabtagene Maraleucel Across a Variety of Clinical Sites From Three Ongoing Clinical Studies in Relapsed/Refractory Large B-Cell Lymphoma.” (Abstract 8037)

• **Debra Richardson, MD**, Stephenson Cancer Center at the University of Oklahoma, will present on “Phase I Expansion Study of XMT-1536, a Novel NaPi2b-Targeting Antibody-Drug Conjugate: Preliminary Efficacy, Safety, and Biomarker Results in Patients with Previously Treated Metastatic Ovarian Cancer or Non-Small Cell Lung Cancer.” (Abstract 3549)

• **Gerald Falchook, MD, MS**, Director of Drug Development for Sarah Cannon Research Institute at HealthONE, will present on “Pen-866, a Miniature Drug Conjugate of a Heat Shock Protein 90 (HSP90) Ligand Linked To SN38 For Patients with Advanced Solid Malignancies: Phase I and Expansion Cohort Results.” (Abstract 3515)

• Elisa Fontana, MD, Clinical Research Fellow at Sarah Cannon Research Institute – UK, will present on “Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer With Or Without Oxaliplatin: Individual Patient Data Meta-Analysis of Three Randomized Controlled Trials with Subgroup Analyses of Age Cohorts.” (Abstract 4074)

• **Andrew McKenzie, PhD**, Senior Manager of Personalized Medicine, will present on “Clinical and Genomic Analysis of Non-Small Cell Lung Cancer Patients with MET Exon14 Skipping (METex14) Mutations and Responses To Anti-MET Therapy.” (Abstract 9613)

The researchers represent Sarah Cannon’s global network of strategic sites: Sarah Cannon Research Institute at Tennessee Oncology, Sarah Cannon Research Institute at Florida Cancer Specialists, Colorado Blood Cancer Institute, Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Sarah Cannon Center for Blood Cancer at TriStar Centennial, Sarah Cannon Research Institute at HCA Midwest Health (Kansas City), Sarah Cannon Research Institute at HealthONE (Denver), Sarah Cannon Research Institute - United Kingdom, Sidney Kimmel Cancer Center at Jefferson Health, and The Stephenson Cancer Center at the University of Oklahoma.

**About Sarah Cannon Research Institute**
Sarah Cannon Research Institute is the research arm of HCA Healthcare’s Cancer Institute, Sarah Cannon. Focused on advancing therapies for patients, it is one of the world’s leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom. A leader in drug development, Sarah Cannon has led more than 400 first-in-human clinical trials since its inception in 1993, and has been a clinical trial leader in the majority of approved cancer therapies over the last 10 years. Additionally, Sarah Cannon offers management, regulatory, and other research support services for drug development and industry sponsors as well as strategic investigator sites through its contract research organization (CRO), Sarah Cannon Development Innovations. For more information, visit sarahcannon.com.